Full-Time

Zone Business Director

Confirmed live in the last 24 hours

Travere Therapeutics

Travere Therapeutics

201-500 employees

Develops therapies for rare diseases

Compensation Overview

$181k - $235k/yr

+ Cash Compensation + Short-term Incentive + Long-term Incentive + Company Stock

Senior, Expert

Waterbury, CT, USA + 2 more

More locations: New York, NY, USA | Massachusetts, USA

Candidates must live in their zone or immediate adjacency.

Category
Strategic Account Management
Sales & Account Management
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Travere Therapeutics referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • Bachelor’s degree in related Life Sciences discipline
  • MBA preferred
  • Minimum of 10 years of industry experience in a complex selling model or relevant work experience
  • Minimum of 3 years of experience in sales management in Biotech or Pharmaceutical industry or demonstrated equivalent leadership experience within Travere
  • Ability to effectively deliver and manage performance, engage team members, provide coaching, and respond to situations affecting staff
  • Entrepreneurial mindset and “hands on” leadership experience
  • Strong experience in exceeding corporate patient acquisition and revenue goals
  • Excellent collaboration skills with strong attention to detail and relationships
  • Background check including Motor Vehicle Record
  • Ability to travel 60-80% domestically (mainly within the zone)
  • The position is field based and the candidate must live in their zone or immediate adjacency.
Responsibilities
  • Fosters a culture of patient-centricity, accountability, collaboration, compliance, fun, and high-performance.
  • Shapes the environment that provides the right balance of autonomy, support, and development to enable the Zone to meet and exceed goals and objectives.
  • Develop Zone business plans based on sales goals, sales and marketing plans, expectations and available resources for the purpose of meeting or exceeding sales forecasts.
  • Effectively manage Zone operating budgets, provide expense management guidance to Clinical Account Managers (reps) and ensure corporate expense policy is followed.
  • Recruit, hire, train and supervise Clinical Account Managers within Zone.
  • Utilize field time to provide individual development of Clinical Account Managers.
  • Be an expert in the clinical data of the product and be able to provide direction for its use.
  • Actively develop Clinical Account Managers for additional responsibilities and future roles.
  • Provide reviews, evaluate performance, assign merit increases and implement performance improvement plans for Clinical Account Managers.
  • Interface with internal Commercial Team to provide feedback and input for development of sales and marketing plans.
  • Personally develop strong relationships with KOLs, physicians, academic centers, and other key market stakeholders to foster acceptance of the Company’s products.
  • Demonstrate leadership by serving as a role model of the organizations’ corporate values.
Desired Qualifications
  • Experience in rare disease or highly specialized products.
  • Experience with products in specialty pharmacy distribution.
  • Nephrology experience.
  • Experience promoting/managing promotion to academic institution settings.
  • Direct recruitment, hiring, training, coaching and development of a sales team.

Travere Therapeutics focuses on creating therapies for individuals affected by rare diseases. The company identifies specific rare conditions and develops treatments aimed at improving the quality of life for these patients. Their approach involves extensive research and collaboration with the medical community to ensure that the therapies they create are effective and meet the needs of those living with these conditions. Unlike many pharmaceutical companies that may prioritize more common diseases, Travere Therapeutics is dedicated to addressing the unique challenges faced by patients with rare diseases. The ultimate goal of the company is to provide life-changing therapies that enhance the lives of individuals living with these conditions.

Company Size

201-500

Company Stage

IPO

Headquarters

San Diego, California

Founded

2008

Simplify Jobs

Simplify's Take

What believers are saying

  • Raised $144 million in 2024 to support clinical development and strategic initiatives.
  • Integration of digital health technologies can improve clinical trial processes.
  • Expansion of telemedicine services facilitates better patient monitoring and follow-up care.

What critics are saying

  • Increased competition in the IgAN treatment market from Calliditas Therapeutics.
  • Potential talent drain as key personnel leave for other companies.
  • Market volatility in biotech sector could impact stock performance and funding.

What makes Travere Therapeutics unique

  • Focus on rare diseases sets Travere apart in the biopharmaceutical industry.
  • Strong collaboration with patient advocacy groups enhances drug development processes.
  • Commitment to personalized medicine increases treatment efficacy for rare diseases.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Paid Vacation

Wellness Program

Company Equity

Company News

Travere Therapeutics
Jan 23rd, 2025
Retrophin, LLC Completes Series A Financing | Travere Therapeutics, Inc.

The Investor Relations website contains information about Travere Therapeutics, Inc. 's business for stockholders, potential investors, and financial analysts.

Travere Therapeutics
Jan 23rd, 2025
Retrophin Completes Reverse Merger With Desert Gateway, Inc. | Travere Therapeutics, Inc.

The Investor Relations website contains information about Travere Therapeutics, Inc. 's business for stockholders, potential investors, and financial analysts.

CSIMarket
Nov 13th, 2024
Travere Therapeutics Raises $143.8M in Offering

Travere Therapeutics announced on November 12, 2024, that it raised approximately $144 million through a public offering, selling 8,984,375 shares at $16 each, including 1,171,875 shares from underwriters' overallotment options. The funds will support clinical development, operations, and strategic initiatives. This move comes amid challenging biotech market conditions and aims to address unmet medical needs in rare diseases. Travere also shared updates on its talent acquisition strategy.

Travere Therapeutics
Nov 11th, 2024
Travere Therapeutics Announces Pricing of Public Offering of Common Stock | Travere Therapeutics, Inc.

The Investor Relations website contains information about Travere Therapeutics, Inc. 's business for stockholders, potential investors, and financial analysts.

Stock Titan
Nov 7th, 2024
Travere Therapeutics Announces Proposed Public Offering of Common Stock

Travere Therapeutics (Nasdaq: TVTX) has announced plans for an underwritten public offering of its common stock.